scholarly journals Optimization of psoriasis assessment system based on patch images

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Cho-I. Moon ◽  
Jiwon Lee ◽  
HyunJong Yoo ◽  
YooSang Baek ◽  
Onseok Lee
Keyword(s):  
Severity Index ◽  
The Body ◽  
Assessment System ◽  
Segmentation Method ◽  
Scoring Method ◽  
Psoriasis Area Severity Index ◽  
Pasi Score ◽  
Psoriasis Lesion ◽  
Specific Evaluation

AbstractPsoriasis is a chronic inflammatory skin disease that occurs in various forms throughout the body and is associated with certain conditions such as heart disease, diabetes, and depression. The psoriasis area severity index (PASI) score, a tool used to evaluate the severity of psoriasis, is currently used in clinical trials and clinical research. The determination of severity is based on the subjective judgment of the clinician. Thus, the disease evaluation deviations are induced. Therefore, we propose optimal algorithms that can effectively segment the lesion area and classify the severity. In addition, a new dataset on psoriasis was built, including patch images of erythema and scaling. We performed psoriasis lesion segmentation and classified the disease severity. In addition, we evaluated the best-performing segmentation method and classifier and analyzed features that are highly related to the severity of psoriasis. In conclusion, we presented the optimal techniques for evaluating the severity of psoriasis. Our newly constructed dataset improved the generalization performance of psoriasis diagnosis and evaluation. It proposed an optimal system for specific evaluation indicators of the disease and a quantitative PASI scoring method. The proposed system can help to evaluate the severity of localized psoriasis more accurately.

scholarly journals A Nonimmunosuppressant Approach on Asia Psoriasis Subjects: 5-Year Followup and 11-Year Data Analysis

2012 ◽  
Vol 2012 ◽  
pp. 1-11
Author(s):  
Tony Yuqi Tang
Keyword(s):  
Severity Index ◽  
Adverse Event Reporting ◽  
Efficacy And Safety ◽  
Psoriasis Area Severity Index ◽  
Telephone Interviews ◽  
Liver Function Testing ◽  
Pasi Score ◽  
Psoriasis Lesion ◽  
Function Testing ◽  
Monthly Visit

Mono- or combine immunosuppressants are commonly used for psoriasis; however the side effect caused by potent systemic immunosuppressants frequently incurred; moreover the inflammation flares up shortly after immunosuppressants are discontinued. An alternative nonimmunosuppressive therapy was introduced to psoriasis subjects. A retrospective observational study consisted of 1583 psoriasis patients who were treated with Herose Psoria capsule 1440 mg three times daily at two clinical centres, one in China, the other in Singapore, from 1 January 2000 to 1 January 2011. Psoriasis lesion evolution was photographed at monthly visit, and efficacy and safety were assessed using psoriasis area severity index PASI score grading, renal and liver function testing, and adverse event reporting and supplemented by information obtained during targeted telephone interviews. The effectiveness of Herose on psoriasis was inversely associated to prior immunosuppressants exposure (r=0.9154), significant improvements occurred in non-immunosuppressants subjects, and complete clearance was achieved in 8 months (87.5%, 14 of 16); the wavelike evolution of psoriatic lesion appeared in prior immunosuppressants subjects.

scholarly journals Successful Certolizumab Pegol Treatment of Chronic Anterior Uveitis Associated with Psoriasis Vulgaris

2018 ◽  
Vol 9 (3) ◽  
pp. 499-503 ◽  
Author(s):  
Keiko Yamaguchi ◽  
Takaaki Hayashi ◽  
Genichiro Takahashi ◽  
Mami Momose ◽  
Akihiko Asahina ◽  
...  
Keyword(s):  
Anterior Uveitis ◽  
Psoriasis Vulgaris ◽  
Certolizumab Pegol ◽  
Severity Index ◽  
The Body ◽  
Psoriasis Area Severity Index ◽  
Necrosis Factor Alpha ◽  
Pasi Score ◽  
Factor Alpha ◽  
Grade 3

This report presents details on a 45-year-old male Japanese patient with chronic and refractory anterior uveitis associated with psoriasis vulgaris who was administered certolizumab pegol (CZP), which is an anti-tumor necrosis factor alpha (TNF-α) monoclonal antibody. Although CZP has only been formally approved for rheumatoid arthritis treatment in Japan, a clinical trial allowed us to assess CZP effectiveness in this patient. The grade 3+ anterior chamber inflammation (for both the cells and flare) observed at baseline improved to grade 0 at 3 months post-treatment. Dermatologically, the psoriasis area severity index (PASI) score was 25.4, while the body surface area (BSA) was 88% at baseline. At 3 months after treatment, the scores improved to 2.8 for PASI and less than 1% for BSA. After the treatment, remission has lasted for at least 9 months. No adverse events were seen during the CZP treatment. These findings suggest that CZP could be an effective therapeutic alternative in some refractory anterior uveitis patients with psoriasis vulgaris.

scholarly journals Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long-term treated HIV infection: A case report

2019 ◽  
Vol 7 ◽  
pp. 2050313X1984519 ◽  
Author(s):  
Misha Zarbafian ◽  
Benoit Cote ◽  
Vincent Richer
Keyword(s):  
Hiv Infection ◽  
Opportunistic Infections ◽  
Total Body Surface Area ◽  
Undetectable Viral Load ◽  
Severity Index ◽  
Severe Psoriasis ◽  
Psoriasis Area Severity Index ◽  
Quality Of Life Index ◽  
Pasi Score ◽  
Total Body

Treatment of moderate-to-severe psoriasis in patients with HIV infection is a clinical challenge. We present the case of a patient with a longstanding history of well-controlled HIV. He had failed topical management, and his hypertriglyceridemia made use of acitretin potentially unsafe. He was unable to regularly attend a phototherapy unit. Physical examination revealed 12% total body surface area involvement with a Psoriasis Area Severity Index (PASI) of 10.2. His Dermatology Quality of Life Index (DLQI) was 20. After 3 months of apremilast treatment, his PASI decreased to 4.1. After 7 months, his PASI decreased to 2.7 and his DLQI to 1. Two years later, his PASI score was 2.4, with a stable CD4 count of 1200 cells/mm3 and an undetectable viral load. There were no serious opportunistic infections or laboratory abnormalities. To our knowledge, this represents the second reported case of psoriasis treatment with apremilast in a patient with HIV.

scholarly journals Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: a US and EU Real-world Evidence Study

2021 ◽  
Author(s):  
Marieke M.B. Seyger ◽  
Matthias Augustin ◽  
Michael Sticherling ◽  
Teresa Bachhuber ◽  
Juanzhi Fang ◽  
...  
Keyword(s):  
Severe Disease ◽  
Topical Therapy ◽  
Significant Proportion ◽  
Unmet Need ◽  
Severity Index ◽  
Paediatric Population ◽  
Cross Sectional Survey ◽  
Psoriasis Area Severity Index ◽  
Cross Sectional ◽  
Pasi Score

This study is a retrospective analysis using data collected from the Adelphi Paediatric Psoriasis Disease-Specific Programme cross-sectional survey. Despite being treated for their psoriasis, a substantial proportion of paediatric patients presented with moderate (18.3%) or severe (1.3%) disease at sampling; 42.9% and 92.0% had a body surface area (BSA) of >10%, and 38.8% and 100.0% had a Psoriasis Area Severity Index (PASI) score >10, respectively. Overall, 69.9% of patients had only ever been treated with a topical therapy for their psoriasis. For patients with moderate or severe disease at sampling, 16.3% and 14.4% were currently receiving conventional systemics or biologic therapy, respectively. There is a clinical unmet need in this paediatric population; a considerable percentage of patients still experienced moderate or severe disease and persistent psoriasis symptoms, with numerous body areas affected. A significant proportion of patients were undertreated, which may explain the high burden of disease observed.

Psoriasis: Wechsel der Medikamentenklasse bei Nichtansprechen?

2020 ◽  
Vol 8 (1) ◽  
pp. 16-18 ◽  
Author(s):  
Sandra Philipp
Keyword(s):  
Quality Of Life ◽  
Severity Index ◽  
Biologic Agents ◽  
Efficacy And Safety ◽  
Serious Adverse Events ◽  
Psoriasis Area Severity Index ◽  
Drug Survival ◽  
Quality Of Life Index ◽  
Pasi Score

Background: Switching between biologics is commonly performed for the management of plaque psoriasis. However, no evidence about switching from secukinumab to ustekinumab has been reported. Methods: This retrospective observational multicenter study aimed to describe efficacy and safety of ustekinumab in secukinumab nonresponder patients. Results: A total of 21 patients unresponsive to secukinumab were treated with ustekinumab for a mean period of 53.3 weeks. Ustekinumab was effective in reducing disease severity, with significant improvements of both psoriasis area severity index (PASI) and dermatology quality of life index (DLQI) scores. PASI score improvements of 31.8, 44, 77.8, 80.3, 80.5, and 89.6%, at week 4, 12, 24, 36, 48, and above 60 weeks, respectively, were detected (p<0.05), achieving PASI 50, 75, and >90 responses in 93.8, 87.5, and 50% of patients at week 48. Four patients withdrew from ustekinumab treatment because of inefficacy, and failure of multiple biologic agents (>2) seemed to affect ustekinumab drug survival. No serious adverse events (AEs) were reported while 38.1% of patients experienced mild AEs. Conclusion: Ustekinumab was safe and effective in treating patients unresponsive to secukinumab.

scholarly journals Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters

Life ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 535
Author(s):  
Éva Anna Piros ◽  
Ákos Szabó ◽  
Fanni Rencz ◽  
Valentin Brodszky ◽  
Norbert Wikonkál ◽  
...  
Keyword(s):  
Body Composition ◽  
Serum Lipid ◽  
Density Lipoprotein ◽  
Severity Index ◽  
The Body ◽  
Lipoprotein Cholesterol ◽  
Baseline Body Mass Index ◽  
Interleukin 17 ◽  
Psoriasis Area Severity Index ◽  
Inflammatory Parameters

BACKGROUND: Psoriasis is frequently accompanied by metabolic syndrome. Effect of anti-tumor necrosis factor therapies on increases in body weight is well-known. Data on the effects of interleukin-17 inhibitors are limited. Authors determined the effect of anti-interleukin-17 therapies on the body composition and serum lipid and inflammatory parameters among severe psoriatic patients. METHODS: Thirty-five severe psoriatic patients were enrolled. Twenty-two received secukinumab and 13 received ixekizumab as their 2nd-or 3rd-line biological treatment. Before treatment initiation and 6 months later, laboratory examinations measuring metabolic and inflammatory panels and body composition analyses were performed. RESULTS: After 6 months, a significant reduction was observed in psoriasis area severity index (p < 0.001) from 18 to 0, in c-reactive protein (p < 0.001) from 6.6 to 4.00 mg/L, in low-density lipoprotein-cholesterol (p = 0.004) from 3.69 to 3.19 mmol/L, and an improvement in high-density lipoprotein-cholesterol (p = 0.022) from 1.31 to 1.40 mmol/L. Median baseline body mass index was 32.80 kg/m2. The body composition parameters did not show any significant changes. CONCLUSIONS: Anti-interleukin-17 therapy of severe psoriatic patients does not cause significant changes in body composition parameters. Improvements in the lipid and inflammatory parameters might have a beneficial effect on patients’ cardiometabolic status. This effect might be detectable in high-risk obese psoriatic patients.

scholarly journals THE ROLE OF SHAMAN CHIKITSA IN EKAKUSHTHA WITH SPECIFIC REFERENCE TO PSORIASIS: A CASE STUDY

2021 ◽  
pp. 62-67
Author(s):  
Sushir Pavan Dnyandeo ◽  
Umate Pooja Suresh ◽  
Chawre Sushil Vilas
Keyword(s):  
Skin Color ◽  
Skin Diseases ◽  
Symptomatic Relief ◽  
Severity Index ◽  
Modern Medicine ◽  
Specific Reference ◽  
Psoriasis Area Severity Index ◽  
Life Style Changes ◽  
Pasi Score ◽  
Long Course

Skin diseases are increases day by day due to unhealthy food habits and life style changes. People are also very cautious about the skin problem because of skin is the mirror which reflects the harmony of internal functions of body. Any change in skin color disturbs the patient both mentally and physically. Psoriasis is chronic inflammatory, hyperproliferative skin disease. It is an autoimmune disease in which scaling and itching of skin present. Because of its recurrent nature the disease has remained a great problem. There is no definite cure for this disease till now. Modern medicine provides symptomatic relief but also has side effects in long course. Here an effort was made to treat a sixty-four years old male diagnosed case of Plaque Psoriasis, by combined Ayurvedic regimen. The Ayurvedic diagnosis is considered as Ekakushtha which is a Vata Kapha predominant Kshudrakushtha. As the principle of treatment, all types of Kushtha will be treated with Samshodhana and Samshamana. In Covid pandemic, Shamana Chikitsa was preferably given for 45 days. PASI (Psoriasis area severity index) score was taken for assessment criteria. PASI score before starting the treatment was found to be 9.6 which decreased to 0.4 at the end of treatment. Also, significant improvements in subjective parameters were observed. This case report showed that combined Ayurvedic modalities resulted in great improvement in overall condition of the patient with no recurrence in five months follow-up. Such a combine Ayurvedic modalities can be very useful in the management of Psoriasis and betterment of mankind.

scholarly journals PSORIASIS VULGARIS PADA BAYI

2014 ◽  
Vol 6 (1) ◽  
Author(s):  
Shienty Gaspersz ◽  
Herry E. J. Pandaleke
Keyword(s):  
Vitamin D3 ◽  
Psoriasis Vulgaris ◽  
Age Of Onset ◽  
Severity Index ◽  
Psoriasis Area Severity Index ◽  
Normal Limits ◽  
Severity Index Score ◽  
Pasi Score ◽  
Erythematous Plaques ◽  
Topical Emollient

Abstract: Psoriasis may begin at any age but most often after puberty and only about 2% occurs in less than 2 years of age. The age of onset plays an important role because early onset psoriasis accompanied by a psoriasis family history is more severe and has a tendency to relapse. The treatment for mild psoriasis is topical and phototherapy. The first-line treatment is topical emollient, glucocorticoids, and vitamin D3 analog. We reported a case of a 3-month-old female infant presenting erythematous plaques with scales on scalp, face, neck, chest, tummy, armpit, back, buttock, and groin accompanied with irritability that had occured for a week. The Psoriasis Area Severity Index score (PASI) was 7% and laboratory examinations were within normal limits. Treatment with topical desonide 0.05% for 1 week did not result in any improvement. The treatment was changed to topical mometason furoat 0.1%. After 7 weeks of therapy, the plaques became flattened and less pigmented, and the PASI score decreased to 0.9%.Keywords: psoriasis vulgaris, infant  Abstrak: Usia awitan psoriasis bervariasi dari bayi hingga usia lanjut, namun sebagian besar timbul setelah pubertas dan hanya sekitar 2% terjadi pada usia kurang dari 2 tahun. Usia awitan perlu diketahui karena semakin dini usia awitan disertai adanya riwayat keluarga dengan psoriasis, perjalanan penyakit akan makin berat dan makin sering kambuh. Pilihan pengobatan pada psoriasis ringan (< 10%) ialah pengobatan topikal dan fototerapi. Pengobatan topikal lini pertama ialah emolien, glukokortikoid, dan analog vitamin D3. Kami melaporkan seorang bayi perempuan berusia 3 bulan yang datang dengan plak eritematosa, berbatas tegas, ukuran bervariasi, dengan skuama pada kepala, wajah, leher, dada, perut, ketiak, punggung, bokong, dan selangkangan, disertai rewel sejak 1 minggu lalu. Perhitungan Psoriasis Area Severity Index (PASI) 7%. Pemeriksan laboratorium masih dalam batas normal. Pasien diterapi dengan krim desonide 0,05%, namun setelah 1 minggu tidak terdapat perbaikan yang memuaskan, sehingga diganti dengan krim mometason furoat 0,1%. Setelah 7 minggu menggunakan mometason furoat, bercak merah yang awalnya meninggi menjadi hipopigmentasi dan mendatar serta perhitungan PASI menjadi 0,9%.Kata kunci: psoriasis vulgaris, bayi

scholarly journals Effects of Rusanda Spa balneotherapy combined with calcipotriol on plaque psoriasis

2015 ◽  
Vol 72 (11) ◽  
pp. 1010-1017 ◽  
Author(s):  
Zoran Golusin ◽  
Marina Jovanovic ◽  
Natasa Magda ◽  
Slobodan Stojanovic ◽  
Milan Matic ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Therapeutic Efficacy ◽  
Clinical Symptoms ◽  
Severity Index ◽  
Mineral Waters ◽  
Treatment Modalities ◽  
Psoriasis Area Severity Index ◽  
Randomized Controlled ◽  
Plaque Type ◽  
Pasi Score

Background/Aim. Treatment of psoriasis is very complex and there are no still universal, nor unique treatment modalities. Apart from conventional treatment, which includes topical calcipotriol (vitamin D3 analogue), balneotherapy is drawing increased attention worldwide. Being part of climatotherapy, balneotherapy is defined as the use of natural environmental factors in the treatment of health conditions, whereas in the treatment of psoriasis it means the use of mineral baths and peloids. The aim of this study was to examine the therapeutic efficacy of mineral waters and peloids of the Rusanda Spa on plaque psoriasis in patients also treated with calcipotriol. Methods. The study included 60 patients divided into two groups. The first group included patients treated with mineral waters, peloids and calcipotriol in the Rusanda Spa, while the second one included those treated only with calcipotriol. The study took 21 days, and each patient was followed up for at least one month after ending the treatment. The treatment efficacy was measured by psoriasis area severity index (PASI) scores on the days 0, 7, 14 and 21 during the treatment and 30 after the end of the therapy. Results. After a 3-week treatment in the Rusanda Spa, the first group showed a decrease in PASI score by 59.45%, whereas in the group of outpatients treated by calcipotriol it was 39.34%. On the day 30 following the treatment, the first group presented with the PASI score reduction of 58.44%, and the second group of 34.78%. The therapeutic efficacy of mineral waters and peloids combined with calcipotriol showed to be significantly higher in regard to monotherapy with calcipotriol (p < 0.05). In regard to clinical symptoms, the best results were obtained in the reduction of desquamation (p < 0.001). Conclusion. The results of our study show that in the treatment of plaque-type psoriasis, topical calcipotriol combined with Spa Rusanda balneotherapy is more effective than topical calcipotriol alone. Randomized controlled trials are needed to confirm the effects of balneotherapy as monotherapy in treatment of this type of psoriasis.

Sign in / Sign up

Export Citation Format

Share Document